If you have been reading about aggregation and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-02-22. Where a claim depends on a specific study, the study is described rather than over-claimed.
The choice of solvent is guided by peptide properties and the intended downstream use. Water alone can dissolve many hydrophilic peptides, while hydrophobic sequences may require a small amount of an organic solvent or a buffered solution. Some peptides carry net charges that affect solubility across pH values. The pH of the final solution can influence stability and aggregation. In research settings, the solvent is selected to match the assay or analytical method rather than for any therapeutic purpose.
During reconstitution, liquid is directed toward the wall of the vial rather than forcefully onto the powder. Gentle swirling or inversion mixes the contents without creating excessive foam or shear. Foaming can denature some peptides and can make volume measurement difficult. Complete dissolution is often confirmed by visual inspection against a light source. Particles, cloudiness, or undissolved material may indicate incomplete mixing, aggregation, or a solubility limitation that requires further investigation.
Analytical checks can detect changes in a reconstituted stock over time. Reverse-phase high-performance liquid chromatography can show loss of main peak, new impurity peaks, or altered retention. Mass spectrometry confirms molecular identity and can reveal modifications. Visual inspection for particles, color change, or turbidity provides a simple first check. If a solution shows signs of degradation or contamination, it is typically discarded rather than re-purified in a routine laboratory.
Once a peptide is dissolved, its solution is generally less stable than the dry powder. Chemical pathways such as hydrolysis, oxidation, and deamidation can alter the molecule, while physical processes can form aggregates or cause adsorption to container walls. The rate depends on pH, buffer composition, temperature, concentration, and the specific sequence. Aqueous stocks are therefore kept cold and used within a defined period. Stability testing is usually performed for each peptide rather than assumed from a general rule.
| Property | Value | Notes |
|---|---|---|
| Physical form | Lyophilized powder or porous cake | Appearance depends on peptide sequence and drying cycle. |
| Solubility class | Sequence-dependent | Hydrophilic peptides often dissolve in water; hydrophobic peptides may require organic co-solvent or buffer. |
| Typical storage temperature (lyophilized) | -20 °C or below | Desiccant, light protection, and limited warming cycles are recommended. |
| Typical storage temperature (reconstituted) | 2–8 °C short term; -20 °C or below long term | Stability varies with pH, buffer, concentration, and peptide sequence; repeated freeze-thaw should be avoided. |
| Common analytical method | RP-HPLC and LC-MS | Used to check purity, identity, and related impurities; not a substitute for sterility testing. |
Buffer components and ionic strength affect how a peptide dissolves and remains in solution. Some sequences require a defined pH range to avoid precipitation or aggregation, while others tolerate pure water. The optimal conditions are often determined empirically because solubility cannot be predicted reliably from sequence alone. Even when a peptide dissolves, the resulting solution may contain aggregates that are not visible to the eye. Analytical methods such as reversed-phase high-performance liquid chromatography and mass spectrometry are used to confirm identity and purity after reconstitution.
Peptide reconstitution is the process of dissolving a dried peptide preparation in a liquid solvent to form a solution. Many peptides are supplied as lyophilized powders because removing water improves stability during shipping and storage. The dried material may appear as a cake, flake, or loose powder depending on the manufacturing and drying method. Reconstitution restores the peptide to a liquid state so that it can be further diluted, analyzed, or handled in laboratory workflows. The term is distinct from dilution, which lowers concentration after a solution already exists.
Aseptic technique is used when a reconstituted solution must remain free of microbial contamination. Work surfaces, gloves, and instruments are cleaned, and the septum of a vial is disinfected before solvent is added. A venting needle or pressure equalization can prevent aerosol formation and pressure buildup. Bacteriostatic water contains an antimicrobial preservative, but preservatives can interfere with some assays or alter peptide behavior. Sterile filtration may be used when a formulation cannot be heat sterilized or when particulates must be removed.
Quality control for reconstituted peptides includes recording lot number, solvent, date, and storage conditions. Visual inspection checks clarity, color, and particles, while pH measurement verifies the expected solution environment. Concentration is often estimated by ultraviolet absorbance at 280 nm for peptides containing tryptophan or tyrosine, or by high-performance liquid chromatography. Mass spectrometry can confirm molecular identity before reconstitution. Sterility testing is relevant when microbial contamination would invalidate an experiment, though such testing is not routinely performed in every laboratory.
Once a peptide is dissolved, water becomes a medium for hydrolysis, oxidation, and deamidation. Dry powders often tolerate ambient shipping better than liquid solutions, but the exact stability profile depends on sequence and formulation. Refrigerated storage near 2 to 8 degrees Celsius or frozen storage at minus 20 or minus 80 degrees Celsius is common in laboratories. Repeated freeze-thaw cycles can promote aggregation, precipitation, or loss of activity. Dividing a solution into single-use aliquots before freezing can reduce the number of temperature cycles.
Reconstitution is the process of dissolving a lyophilized peptide powder in a suitable liquid to produce a solution for laboratory or clinical use. The dry powder is typically a porous cake or fluffy solid formed by freeze-drying an aqueous or mixed-solvent preparation. Adding solvent restores the peptide to a dissolved state, but the result is not necessarily identical to the original pre-lyophilization solution. Factors such as pH, ionic strength, temperature, and the peptide's sequence influence how completely and quickly dissolution occurs. The term is distinct from dilution, which lowers concentration without changing the physical state of an already dissolved material.
Solvent selection depends on the peptide's charge, hydrophobicity, and intended application. Many lyophilized peptides dissolve readily in water, while others require a small amount of a miscible organic solvent, a dilute acid, or a dilute base before aqueous dilution. A buffer may be used when a stable pH range is known, but adding buffer salts can also promote aggregation or precipitation. Dissolution should be observed rather than assumed, because a clear solution does not prove that the peptide is monomeric or fully active. The order of solvent addition and the final volume matter for achieving the intended concentration.
study of complex formation in supramolecular systems – organized ensembles surfactants and macrocyclic ligands; study of coordination compounds of iron (III) and manganese (II) for magnetic resonance imaging; obtaining new types of hybrid organic-inorganic functional materials based on nanoscale hyperbranched structures. Results of these studies are of basic value in the area of coordination chemistry, bioinorganic chemistry, chemistry of nanomaterials, pharmaceutical chemistry. Proposed model and physio-chemical basis of self-assembly of nanoscale of hyperbranched polymers, set new approaches to understanding the mechanisms of gene transfection and targeted drug delivery.
On 1 March, the Department of Food and Veterinary of Lithuania announced that horse meat was found in three canned beef brands sold by Latvian company Kuršu Zeme. Canned beef made by the Latvian company was removed from sale in Lithuania. === Wiljo Import en Export B.V. and Vleesgroothandel Willy Selten B.V. === On 10 April 2013, it was reported that two Dutch trading companies, owned by the same person whom food safety officials had previously investigated, may have supplied 50,000 metric tonnes of adulterated beef containing horse meat since January 2011. On 7 February 2013, it was revealed by the Food Standards Agency that the Findus beef lasagne range in the UK, France, Norway, and Sweden, and the shepherd's pie and moussaka ranges in France, contained horse meat without proper declaration or official scrutiny. The contamination may have gone on since summer 2012 according to a leaked document.
Smith was hired to become the defensive quality control coach for the Tennessee Titans in 2011 under new head coach Mike Munchak. Smith then became the offensive quality coach the following season. In 2013, Smith was promoted to the assistant offensive line and assistant tight ends coach. Munchak was fired after the 2013 season and new head coach Ken Whisenhunt retained Smith as the assistant tight ends coach. Midway through the 2015 season, Whisenhunt was fired and replaced by tight ends coach Mike Mularkey. Mularkey was kept as head coach for the 2016 season and Smith was promoted to the new tight ends coach. When Mularkey was fired after the 2017 season, new head coach Mike Vrabel kept Smith as the tight ends coach for 2018. On January 21, 2019, Smith was promoted to offensive coordinator, replacing Matt LaFleur, who departed to become head coach of the Green Bay Packers two weeks prior. In his first year as offensive coordinator, Smith oversaw the highest-scoring Titans team in 16 years, with Derrick Henry, Ryan Tannehill, and Jonnu Smith having career years. Smith was praised for his play-calling in the Titans' 28–12 road victory over the top-seeded Baltimore Ravens in the AFC Divisional Round. In 2020, the Titans ranked fourth in scoring and second in total yards.
Following subcutaneous injection, albiglutide reaches highest blood concentrations after three to five days. Steady-state concentrations are achieved after three to five weeks. The substance is most likely broken down by protease enzymes to small peptides and amino acids. Being resistant to dipeptidyl peptidase-4 (DPP-4), the enzyme that breaks down GLP-1, albiglutide has a biological half-life of five (4–7) days, which is considerably longer than the older GLP-1 analogs exenatide and liraglutide. This allows for a once-weekly administration, unlike liraglutide but like the extended-release form of exenatide. Albiglutide is a peptide consisting of 645 proteinogenic amino acids with 17 disulfide bridges. Amino acids 1–30 and 31–60 constitute two copies of modified human GLP-1, the alanine at position 2 having been exchanged for a glycine for better DPP-4 resistance. The remaining sequence is human albumin. The complete sequence is
Gas exchange must be restored as quickly as possible to avoid collateral damage, so activated lymphocytes secrete IFNγ to stimulate the production of matrix metalloproteinase MMP-9 by macrophages. AMs have been reported to produce MMP-9 partly via PGE2-dependent PKA signaling pathways, which are the pathways involved in the inhibition of phagocytosis. MMP-9 activates latent TGF-β, reinducing expression of αvβ6 integrins on alveolar epithelial cells, thereby returning the alveolar macrophage to a resting state. Activation of TGF-β is also advantageous because its production stimulates collagen synthesis in interstitial fibroblasts, which is necessary for restoring alveolar wall architecture. List of human cell types derived from the germ layers Histology image: 13906loa – Histology Learning System at Boston University - "Respiratory System: lung (human), alveolar macrophages" Histology at KUMC resp-resp16 "Alveoli" Slide at ufl.edu
Sources: en.wikipedia.org
In addition to cell signaling, the mTOR pathway also plays a role in beta cell growth leading to insulin secretion. High glucose in the blood begins the process of the mTOR signaling pathway, in which leucine plays an indirect role. The combination of glucose, leucine, and other activators cause mTOR to start signaling for the proliferation of beta cells and the secretion of insulin. Higher concentrations of leucine cause hyperactivity in the mTOR pathway, and S6 kinase is activated leading to inhibition of insulin receptor substrate through serine phosphorylation. In the cell the increased activity of mTOR complex causes eventual inability of beta cells to release insulin and the inhibitory effect of S6 kinase leads to insulin resistance in the cells, contributing to development of type 2 diabetes. Metformin is able to activate AMP kinase which phosphorylates proteins involved in the mTOR pathway, as well as leads to the progression of mTOR complex from its inactive state to its active state. It is suggested that metformin acts as a competitive inhibitor to the amino acid leucine in the mTOR pathway.
ALK-positive ALCL is diagnosed by histological and immunological examinations of involved tissues, typically lymph nodes. These tissues have lymphoma-like infiltrates that have variable numbers of ALCL "hallmark" cells, i.e. cells with kidney- or horseshoe-shaped nuclei that strongly express CD30 as detected by immunohistochemistry and an ALK fusion protein as detected by fluorescence in situ hybridization. These cells are scattered throughout the infiltrates. WHO classifies these infiltrates into 5 patterns: a common pattern consisting of large variably shaped cells with large nuclei that typically contain multiple nucleoli (60–70% of cases); a small-cell pattern consisting of small to medium-sized neoplastic cells with clear cytoplasm and "hallmark" cells that are concentrated around small blood vessels (5–10% of cases); a lymphohistiocytic pattern consisting of small neoplastic cells along with abundant histiocytes (10% of cases); a Hodgkin's-like pattern in which the architecture resembles the nodular sclerosis pattern of Hodgkin lymphoma (3% of cases); and a composite pattern consisting of two or more of the just described patterns (15% of cases). Detection of circulating autoantibody against ALK supports the diagnosis. Individuals with low levels of these autoantibodies are at an increase risk of relapsing after treatment.
While the initial consolidation of Air Force laboratories reduced overhead and budgetary pressure, another push towards a unified laboratory structure came in the form of the National Defense Authorization Act for Fiscal Year 1996, Section 277. This section instructed the Department of Defense to produce a five-year plan for consolidation and restructuring of all defense laboratories. The currently existing laboratory structure was created in October 1997 through the consolidation of Phillips Laboratory headquartered in Albuquerque, New Mexico, Wright Laboratory in Dayton, Ohio, Rome Laboratory (formerly Rome Air Development Center) in Rome, New York, and Armstrong Laboratory in San Antonio, Texas and the Air Force Office of Scientific Research (AFOSR). The single laboratory concept was developed and championed by Maj Gen Richard Paul, who was Director of Science & Technology for AFMC and Gen Henry Viccellio Jr, and then became the first Commander of AFRL.
An insulin pump delivers insulin subcutaneously. The insulin pump body itself can also contain the algorithm used in an AID system, or it can connect via Bluetooth with a separate mobile device (such as a phone) to send data and receive commands to adjust insulin delivery. Algorithm The algorithm for each AID system differs. In commercial systems (see below), little is known about the details of how the control algorithm works. In open source systems, the code and algorithm are openly available. In general, all algorithms do the same basic functionality of taking in CGM data and based on predicted glucose level's and the user's personal settings (for basal rates, insulin sensitivity, and carbohydrate ratio, for example) then recommends insulin dosing to help bring or maintain glucose levels in target range. Depending on the system, users may have the ability to adjust the target for the system, and may have different settings to ask the system to give more or less insulin in general.
Alexandra C. Newton is a Canadian and American biochemist. She is a Distinguished Professor of pharmacology at the University of California, San Diego. Newton runs a multidisciplinary Protein kinase C and Cell signaling biochemistry and cell biology research group in the School of Medicine, investigating molecular mechanisms of signal transduction in the Phospholipase C (PLC) and Phosphoinositide 3-kinase (PI3 kinase, or PI3-K) signaling pathways. She has been continuously funded by the US National Institutes of Health since 1988. Newton was born in Cape Town, South Africa, and was schooled in Vancouver, Athens, and Aix-en-Provence. She graduated in 1980 from the Simon Fraser University in Canada, where she was awarded a 1st-class honours degree in biochemistry and French literature. She received her PhD in chemistry in 1986 from Stanford University, working with Wray H. Huestis on a thesis examining band 3, a red cell membrane protein.
Sources: en.wikipedia.org
Lyophilized means the material was frozen and then dried under vacuum, leaving a solid powder or cake. The process removes most of the water or solvent. The resulting peptide is typically more stable for storage than a solution.
Hydrophobic peptides may not disperse well in water alone because water cannot effectively solvate nonpolar regions. A small amount of a miscible organic solvent can improve wetting and dissolution. The choice depends on the peptide and the analytical method.
A clear solution indicates that visible particles are absent, but it does not confirm peptide identity, purity, or exact concentration. Those properties require analytical methods such as mass spectrometry and chromatography. Concentration is often estimated from the weighed mass or measured by a validated assay.
No single time applies to all peptides. Storage life depends on sequence, solvent, concentration, and temperature. Stability should be determined experimentally or taken from supplier data for the specific lot.